BioWorld

Jan. 25, 2008

MiddleBrook Soars on FDA OK of Once-Daily Strep Antibiotic

MiddleBrook Pharmaceuticals Inc.'s stock skyrocketed Thursday after the FDA approved its once-daily, extended-release amoxicillin tablet, Moxatag. (BioWorld Today) Read More

Gilead Tops Estimates; Earnings Driven by Strong HIV Franchise

Researchers Make Complete Real, Artificial Chromosome

Orexigen Prices $77M Follow-On as Obesity Trials Move Ahead

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...